ArticleHuman genomics2025
Association of MALAT1 gene polymorphisms with neuroblastoma susceptibility in children from Jiangsu Province.
Article in Human genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundNeuroblastoma, a clinically heterogeneous pediatric tumor, has varying outcomes ranging from spontaneous regression to aggressive metastasis. Recent studies have emphasized non-coding RNAs, particularly long non-coding RNAs (lncRNAs), as crucial regulators of cancer epigenetics. MALAT1 is a dual oncogenic lncRNA with some therapeutic potential but has rarely been studied in neuroblastoma.
methodsWe genotyped three MALAT1 polymorphisms (rs591291 C > T, rs619586 A > G, and rs3200401 C > T) in 402 neuroblastoma patients and 473 controls via TaqMan. Further stratification analysis was conducted to evaluate the potential associations of rs591291 and rs619586 with neuroblastoma risk. Through the GTEx database, we also investigated the impact of MALAT1 gene polymorphisms on the expression of nearby genes and splicing variants. Finally, Kaplan‒Meier analysis conducted via the R2 platform demonstrated the correlation between gene expression and the prognosis of neuroblastoma patients.
resultsWe discovered that the MALAT1 gene rs619586 A > G polymorphism significantly reduced neuroblastoma risk, whereas rs3200401 C > T increased the risk of neuroblastoma. Stratification analysis revealed that these significant associations were more pronounced in specific subgroups. Moreover, MALAT1 rs619586 A > G and rs3200401 C > T are significantly associated with increased expression of another lncRNA, NEAT1. These findings indicate that reduced expression of the NEAT1 gene is linked to a greater risk and poorer prognosis for neuroblastomas.
conclusionsMALAT1 rs619586 A > G and rs3200401 C > T significantly contribute to susceptibility to neuroblastoma, and further research is needed to investigate the underlying mechanisms involved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.